NCT03399539View on ClinicalTrials.gov

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

December 20, 2021

Study Completion Date

February 23, 2024

Conditions
Recurrent Plasma Cell MyelomaT(11;14)
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Venetoclax

Given PO

Trial Locations (3)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

55905

Mayo Clinic, Rochester

63110

Siteman Cancer Center at Washington University, St Louis

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Multiple Myeloma Research Foundation

OTHER

lead

Mayo Clinic

OTHER

NCT03399539 - Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter